What is CAGR? What does CAGR table indicate for Sequent Scientific Ltd?

Compounded average growth rate (CAGR) measures the average annual growth rate compounded year-on-year over a period of time.

Sequent Scientific Ltd Stock Analysis

Mid Cap

Evaluated by 1064 users | BSE: 512529 | NSE: SEQUENT |
Pharmaceuticals & Drugs

P I Drugs & Pharmaceuticals Ltd. established in 1991 is a leading manufacturer, exporter of specialized quality formulations having an objective of fulfilling the diverse demands of pharmaceutical industry.P I Drugs & Pharmaceuticals Ltd. specializes in the manufacturing of the...

Decision Maker

Consolidated basis

The valuation guidance of this company is based on Consolidated basis.

1. Right Stock

2. Right Price

Price Chart

3. Right Time

10 Year X-Ray

Consolidated basis Standalone basis P Consolidated basis P

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

What is a Financial Track Record? How to read this chart in order to understand the data present here?

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Sequent Scientific Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation Value Creation Index Colour Code Guide

	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20
Return on Capital Employed	6%	7.28%	-8.95%	-8.28%	-1.14%	0.66%	1.18%	13.83%	7.43%	8.99%
Value Creation Index	-0.48	-0.37	-1.78	-1.72	-1.10	-0.94	-0.90	0.20	-0.35	-0.22

Growth Parameters	Growth Parameters Colour Code Guide

Net Sales (Rs. Cr.)	312	346	327	455	465	625	684	1,031	1,039	1,179
Y-o-Y Gr. Rt.	-	10.9%	-5.5%	39.4%	2.2%	34.3%	9.4%	50.8%	0.9%	13.5%
Adjusted EPS (Rs.)	0.13	0.44	-4.95	-4.7	-2.48	-0.86	-0.17	5.67	2.17	2.96
Y-o-Y Gr. Rt.	-	238.5%	-1225%	NA	NA	NA	NA	NA	-61.7%	36.4%
Book Value per Share (Rs.)	11.59	11.48	7.09	1.97	3.76	38.69	39.44	25.85	27.86	29.34
Adjusted Net Profit	1.4	4.9	-59.5	-64.2	-37.8	-20.5	-4.1	138	53.6	73.4
Net Op. Cash Flow (Rs. Cr.)	49.6	21.5	-3.8	-44.8	-23.6	-0.1	-7.2	45.2	116	115
Debt to Cash Flow from Ops	3.82	12.51	-81.46	-9.34	-20.1	-5,782.48	-57.81	6.73	2.8	2.87

Difference between Standalone Basis and Consolidated basis? Which method is preferred for Sequent Scientific Ltd. ?

Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.

Sequent Scientific Ltd. should be analysed on a Consolidated basis

CAGR CAGR Colour Code Guide

	9 yrs	5 yrs	3 yrs	1 yr
Net Sales	15.9%	20.4%	19.9%	13.5%
Adjusted EPS	41.5%	NA	NA	36.4%
Book Value per Share	10.9	50.8	-9.4	5.3
Share Price	38.1%	5.4%	30.8%	152.1%

Key Financial Parameter	Performance Ratio Colour Code Guide

	Mar'11	Mar'12	Mar'13	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20
Return on Equity (%)	1.22	3.95	-54.74	-84.6	-51.12	-3.96	-0.43	17	7.91	10.13
Operating Profit Margin (%)	14.65	15.21	-2.39	5.66	4.71	9.52	8.13	11.22	12.77	14.91
Net Profit Margin (%)	-0.77	1.39	-18.21	-14.09	-8.35	-2.95	-0.97	14.3	5.95	7.25
Debt to Equity	1.54	2.19	3.74	15.86	8.26	0.34	0.43	0.48	0.47	0.45
Working Capital Days	208	223	251	210	233	224	314	226	206	189
Cash Conversion Cycle	38	9	6	13	61	76	93	70	79	73

Management X-Ray

Corporate Governance What do we look at?

Corporate Governance

Board Credentials

Promoter's holding

Transparency

Integrity

Shareholding Pattern

Entity	Percentage Holding
Promoters	53.86%
Institutions	14.84%
Non-Institutions	31.30%

Promoter's Holding & Share Pledging

Pledged ^*

43.02

44.56

43.06

41.82

70.72

62.12

71.41

44.60

0.00

* Pledged shares as % of Promoter's holding (%)

FAQs

1. Is Sequent Scientific Ltd a good quality company?

MoneyWorks4Me analysed the past 10-year performance of Sequent Scientific Ltd and arrived at the following conclusion:

Past 10 year's financial track record indicates that Sequent Scientific Ltd is a average quality company. However, for specific investment actions please connect with your investment advisor.

2. Is current market price of Sequent Scientific Ltd a good price to buy it?

The 5-year analysis of Sequent Scientific Ltd's performance infers:

Sequent Scientific Ltd earnings have grown by 0%, whereas share price has appreciated 5.4% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

3. What is Sequent Scientific Ltd share price return in the past 10 years ?

We analysed the performance of Sequent Scientific Ltd share prices over the last 10 years. Here is what we found out:

Sequent Scientific Ltd share price has appreciated 28.9% annually over the past ten years.

About Company

P I Drugs & Pharmaceuticals Ltd. specializes in the manufacturing of the formulation belonging to anthelmintic & anti-parasitic segment.

In September 2007 PI Drugs purchased the pharma division of Transchem Limited.

The company is engaged in the business of human health

P I Drugs & Pharmaceuticals Ltd. specializes in the manufacturing of the formulation belonging to anthelmintic & anti-parasitic segment.

In September 2007 PI Drugs purchased the pharma division of Transchem Limited.

The company is engaged in the business of human health & animal health and enjoys high Image for distribution in domestic as well as international markets.

They have a specialized and dedicated WHO - GMP accredited manufacturing plant for the manufacture of API's. It exports to all major markets like Europe, South America, Australia, Asia and Africa.

They started with the introduction of Albendazole and has developed core competency in chemistry of Benzimadazole in very short time.

Product range of the company includes:

Human / Veterinary Formulations